ACSH Cited In International Business Times On "Evergreening" Drugs

By ACSH Staff — Apr 02, 2013
Pharmaceutical companies have long argued that the incentive for creating new drugs is that they retain exclusive rights to sell their inventions for a period of time that s long enough to recover the cost of their investment, and then make a profit off the venture.

Pharmaceutical companies have long argued that the incentive for creating new drugs is that they retain exclusive rights to sell their inventions for a period of time that s long enough to recover the cost of their investment, and then make a profit off the venture. Bringing a new drug to market takes over a decade and costs about $1.3 billion, according to Josh Bloom, director of chemical and pharmaceutical sciences at the American Council on Science and Health. Bloom said in a Wall Street Journal piece from January 2012 that the length of time drugmakers retain exclusive rights has declined from 17 years in the late '60s to 11 years.

ACSH relies on donors like you. If you enjoy our work, please contribute.

Make your tax-deductible gift today!

 

 

Popular articles